Hironobu Ichikawa1, Michio Hiratani2, Akihiro Yasuhara3, Noa Tsujii4, Takashi Oshimo5, Hiroaki Ono6, Yoshihiro Tadori7. 1. Tokyo Metropolitan Children's Medical Center, Tokyo, Japan. 2. Hiratani Clinic for Developmental Disorders of Children, Fukui, Japan. 3. Yasuhara Children's Clinic, Osaka, Japan. 4. Department of Neuropsychiatry, Kindai University Faculty of Medicine, Osaka, Japan. 5. Yoyogi-no-Mori Mental Clinic, Tokyo, Japan. 6. Headquarters of Clinical Development, Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan. 7. Department of Medical Affairs, Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan.
Abstract
AIM: The purpose of this study was to evaluate the long-term safety and efficacy of aripiprazole in treating irritability in pediatric patients (6-17 years) with autistic disorder (AD) in Japan. METHODS: In this open-label extension study, patients who had completed a previous randomized, double-blind, placebo-controlled 8-week study were enrolled and were flexibly dosed with aripiprazole (1-15 mg/day) until the new indication of irritability in pediatric autism spectrum disorder was approved in Japan. RESULTS: Seventy (81%) out of 86 enrolled patients completed week-48 assessments. The mean duration of treatment was 694.9 days. The mean daily dose of aripiprazole over the treatment period was 7.2 mg and the mean of the final dose was 8.5 mg. The most common treatment-emergent adverse events (TEAE; ≥20%) included nasopharyngitis, somnolence, influenza, and increased weight. The majority of these TEAE were mild or moderate in severity, and there were no deaths, and no clinically relevant findings in laboratory values except prolactin decrease, vital signs, height, or ECG parameters. At week 48 (observed case), the mean change from baseline in the Irritability subscale score for the Aberrant Behavior Checklist Japanese Version was -6.3 in prior placebo patients and -2.6 in prior aripiprazole patients. CONCLUSION:Aripiprazole was generally safe, well tolerated, and effective in the long-term treatment of irritability associated with AD in Japanese pediatric patients.
RCT Entities:
AIM: The purpose of this study was to evaluate the long-term safety and efficacy of aripiprazole in treating irritability in pediatric patients (6-17 years) with autistic disorder (AD) in Japan. METHODS: In this open-label extension study, patients who had completed a previous randomized, double-blind, placebo-controlled 8-week study were enrolled and were flexibly dosed with aripiprazole (1-15 mg/day) until the new indication of irritability in pediatric autism spectrum disorder was approved in Japan. RESULTS: Seventy (81%) out of 86 enrolled patients completed week-48 assessments. The mean duration of treatment was 694.9 days. The mean daily dose of aripiprazole over the treatment period was 7.2 mg and the mean of the final dose was 8.5 mg. The most common treatment-emergent adverse events (TEAE; ≥20%) included nasopharyngitis, somnolence, influenza, and increased weight. The majority of these TEAE were mild or moderate in severity, and there were no deaths, and no clinically relevant findings in laboratory values except prolactin decrease, vital signs, height, or ECG parameters. At week 48 (observed case), the mean change from baseline in the Irritability subscale score for the Aberrant Behavior Checklist Japanese Version was -6.3 in prior placebo patients and -2.6 in prior aripiprazolepatients. CONCLUSION:Aripiprazole was generally safe, well tolerated, and effective in the long-term treatment of irritability associated with AD in Japanese pediatric patients.
Authors: Gian Loreto D'Alò; Franco De Crescenzo; Laura Amato; Fabio Cruciani; Marina Davoli; Francesca Fulceri; Silvia Minozzi; Zuzana Mitrova; Gian Paolo Morgano; Franco Nardocci; Rosella Saulle; Holger Jens Schünemann; Maria Luisa Scattoni Journal: Health Qual Life Outcomes Date: 2021-01-25 Impact factor: 3.186